K-Cast

An expert discusses how payers and providers are embracing biosimilars and unbranded biologics as they enter the marketplace.

James Lewis, PharmD, FIDSA, discusses vaccine hesitancy, vaccination status, and accessibility to vaccines across various patient populations.

Medical experts highlight key factors impacting the treatment landscape of spinal muscular atrophy (SMA).

Douglas K Devries, OD, discusses an overview on treatment pathways and burden of disease associated with Demodex blepharitis.

Dr David Rosmarin, MD, explores the treatment landscape and clinical burden associated with vitiligo.

A discussion series reviewing the differences between unbranded biologics and biosimilars and an overview of payer and provider considerations for decision-making.

This content is a production of Managed Healthcare Executive; distribution of this K-Cast is supported by funding from CSL Behring LLC. CSL Behring LLC was not involved in the creation of the content of this production.

Steven Pipe, MD, discusses the treatment options for patients with hemophilia B, including his hope for future management of the bleeding joint disease.

Dr Laura Periman, MD discusses biopsychosocial and economic impacts, as well as innovative treatment opportunities for patients with dry eye disease.

Neal Bhatia, MD, discusses atopic dermatitis and the treatment process, as well as how to improve access to therapies for patients with this disease.

Jennifer Brigitte Green, MD, discusses the management of type 2 diabetes for patients not currently controlled on oral antidiabetic medications.

Expert hematologist/oncologist David R. Gandara, MD, highlights the value comprehensive genomic profiling has in guiding therapeutic decisions.

Recommendations for treating HER2-positive metastatic breast cancer with newer HER2-targeted treatment approaches and considerations regarding their adoption into clinical practice.

Paul K. Paik, MD, discusses the spectrum of targeted therapy in non-small cell lung cancer.

Key opinion leader discusses considerations for adult patients with spinal muscular atrophy (SMA) including disease burden, treatment evaluation, and the use of real-world evidence.